Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

Dutasteride is a safe and effective treatment for hair loss.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Finasteride improves hair growth and satisfaction in men with male pattern baldness but may cause sexual side effects.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.

PLD is an effective and safer alternative for treating breast cancer.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

Developing microRNA-based treatments is hard but has potential.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.